Johnson & Johnson
1Q Revenues: $21.4 billion (+2%)
1Q Earnings: $5.4 billion (loss of $491 million 1Q23)
Comments: Innovative Medicine sales were up 1% to $13.6 billion in the quarter. DARZALEX (daratumumab) sales were $2.7 billion, up 19%. ERLEADA (apalutamide) sales were $689 million, up 27%. CARVYKTI (ciltacabtagene autoleucel) sales were $157 million, up from $72 million in 1Q23. TECVAYLI (teclistamab-cqyv) sales were $133 million, up from 63 million in 1Q23. Other Oncology sales were $178 million, up 80% in the quarter. UPTRAVI (selexipag) sales were up 29% to $468 million and OPSUMIT (macitentan) sales were up 19% to $524 million. TREMFYA (guselkumab) sales were up 26% to $808 million. SPRAVATO (esketamine) sales were up 72% to $225 million. COVID-19 Vaccine sales were down 97% to $25 million. XARELTO sales were down 10% to $518 million. REMICADE sales were down 11% to $434 million. ZYTIGA sales were down 26% to $181 million. CONCERTA sales were down 14% to $177 million.